From Pills To Wafers: Laser Photonics Unveils R&D Initiative For Anti-Counterfeiting And High-Tech Manufacturing

Laser Photonics Corporation LASE launched a research and development initiative to create laser solutions for pharmaceutical tablet drilling, wafer scribing, and semiconductor marking.

Laser Photonics is targeting pharmaceuticals, wafers, and semiconductors through its latest R&D initiative. Following its recent acquisition of Control Micro Systems, the company is committing resources to several new engineering projects to continue advancing its newly acquired laser systems. 

In pharmaceuticals, the company plans to advance Control Micro Systems’ tablet drilling and marking system for time-release medications.

This Class I automated CO2 laser system includes a custom tablet fixture, fume extraction, and machine vision inspection for quality control, offering an effective anti-counterfeiting solution.

Laser technology for wafer serialization involves marking, scribing, and lapping silicon and related compound wafers.

The company plans to enhance Control Micro Systems' multi-station system, designed for wafers up to 300 mm wide and 300–800 microns thick, featuring robotic wafer positioning.

This technology supports production and tracking for applications such as consumer electronics, solar panels, LEDs, MEMS devices, and optoelectronic components.

Laser Photonics will also advance Control Micro Systems’ semiconductor laser marking system, featuring a high-precision ultraviolet laser and galvanometer scanhead for rapid fiducial recognition.

This system creates small, permanent markings on IC mold compounds and ceramics with minimal heat, preventing damage to components. Integrated machine vision ensures accurate chip positioning and marking alignment.

This week, Laser Photonics opened pre-orders for its upcoming CleanTech Industrial Roughening Laser 3060 (CTIR-3060).

Price Action: LASE shares are up 0.36% at $5.63 at the last check Friday.

Read Next:

• Cannabis-Focused RIV Capital Reports 186% YoY Surge In Q3 Revenue Ahead Of Major Merger That Will Cover 25% Of US Population

Image via Unsplash.